Hello, Fool! | Login | Signup | My Fool
Oct 15, 2008 8:21 PM ET | Feedback | Site Changes | Help
The drug development company with three products advancing into late-stage clinical development: Albuferon(r) for chronic hepatitis C, LymphoStat-B(r) for systemic lupus erythematosus, and ABthraxtm for anthrax disease.
View All Commentary (HGSI)
Recs
TMFSarahGen (99.84) Submitted: 7/18/08 3:03 PM : Start Price: $6.11 HGSI Score: 9.51
insiders buying back in march, and technicals look good
Report this Post Replies: 0 | Reply
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Terms & Conditions
RSS Headlines
Fool UK